A Cutaneous Agranular CD2–CD4+CD56+“Lymphoma”: Report of Two Cases and Review of the Literature

Kameoka, Junichi; Ichinohasama, Ryo; Tanaka, Mitsuro; Miura, Ikuo; Tomiya, Yasuo; Takahashi, Shinichiro; Yamada, Minami; Ishikawa, Izumi; Kadowaki, Ikuko; Sasaki, Osamu; Kimura, Jun; Meguro, Kuniaki; Ooya, Kiyoshi; Ito, Sadayoshi

doi:10.1093/ajcp/110.4.478

Cited by 51 publications

(22 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CD4+/CD56+ lymphomas, different from nasal and nasal-type angiocentric natural killer (NK)/T cell lymphomas, were investigated [10, 11, 12]and were designated as blastic NK cell lymphoma/leukemia [11]or cutaneous agranular CD2– CD4+ CD56+ lymphoma [12]. …”

Section: Introductionmentioning

confidence: 99%

Cutaneous Monomorphous CD4- and CD56-Positive Large-Cell Lymphoma

Nagatani

Okazawa²,

Kambara³

et al. 2000

Dermatology

View full text Add to dashboard Cite

Background: Recently, CD56 (NCAM)-positive lymphomas, such as nasal and nasal-type angiocentric NK/T cell lymphoma, aggressive NK cell leukemia/lymphoma and blastic NK cell lymphoma, were described by several authors as a unique group of lymphoma. Objective: In this study, we intend to clarify the clinicopathological features of cutaneous CD4+ and CD56+ lymphoma. Methods: Four patients with cutaneous CD4+ and CD56+ lymphoma were studied. Results: Age at the first examination ranged from 71 to 89 years (mean = 81.2 years). One patient was female and 3 were males. The organ mainly involved at presentation was the skin. Lymphadenopathy, splenomegaly, leukemic spread and central nervous system involvement were observed as the disease progressed. The mean survival time was 12.2 months. Epstein-Barr virus was not detected within the tumor cells. Conclusion: This peculiar lymphoma is different from nasal and nasal-type angiocentric NK/T cell lymphoma and aggressive NK cell leukemia/lymphoma. Similar cases have been reported as blastic NK cell lymphoma/leukemia.

show abstract

Section: Introductionmentioning

confidence: 99%

Cutaneous Monomorphous CD4- and CD56-Positive Large-Cell Lymphoma

Nagatani

Okazawa²,

Kambara³

et al. 2000

Dermatology

View full text Add to dashboard Cite

show abstract

“…Hématodermie CD4+/CD56+, lymphome blastique à cellules NK CD4/CD56+, lymphome cutané non B, non T CD34+/CD56+, plusieurs dénominations ont été attachées à ces nouveaux cas de lymphomes cutanés [2][3][4][5][6]. Il a fallu attendre les progrès de l'immunohistochimie et la découverte d'un marqueur commun, CD56, pour en faire une entité à part entière.…”

Section: Discussionunclassified

Manifestations cutanées révélatrices d’une leucémie aiguë dendritique plasmocytoïde (LADP) : deux observations

et al. 2015

View full text Add to dashboard Cite

“…PDCs have also been found within the parenchyma of different neoplasms [36][37][38] showing a diminished capacity to produce IFN-1a, which may suggest an impaired functional process. 41 It constitutes a relatively novel entity defined by specific clinical, histologic, and immunophenotypical features. This may cause induction of IL-10-producing regulatory T-cells, which in turn suppresses the ability of tumor-infiltrating T-cells to recognize autologous tumor antigens, a well-known factor that predicts tumor progression.…”

Section: Discussionmentioning

confidence: 99%

CD4+/CD56+ Hematodermic Neoplasm

Piña‐Oviedo

Herrera-Medina²,

Coronado³

et al. 2007

Applied Immunohistochemistry &Amp; Molecular Morphology

View full text Add to dashboard Cite

CD4/CD56 hematodermic neoplasm is a rare neoplasm presenting with cutaneous nodules, lymphadenopathy, bone marrow infiltration, and an aggressive clinical course. Recently, the plasmacytoid dendritic cell origin of this neoplasm has been demonstrated. Plasmacytoid dendritic cell is a hematopoietic-derived cell implicated in the regulation of innate and adaptive cell immunity and in the production of certain regulatory cytokines. Recently it has been demonstrated that these cells express cell surface markers such as IL-3 receptor alpha (CD123). In the present report, we describe the clinical, histologic, and immunohistochemical characteristics of 2 cases of CD4/CD56 hematodermic neoplasm. Both patients were male and the age at the time of diagnosis was 36 and 75 years, respectively. Clinical findings were limited to the skin and consisted of multiple cutaneous nodules located in the thorax and extremities, some of them ulcerated. Histologically, the tumors were characterized by a nonepidermotropic, dermal and subdermal infiltration of homogeneous medium-sized cells resembling lymphoblasts or myeloblasts. Immunohistochemical characterization of the tumors showed expression of CD4, CD56, CD43, and CD123, whereas CD8, CD20, and MPO were negative. Immunoreactivity for CD3, which has been described in rare occasions, was found only in one of the cases. This characteristic profile in addition to the expression of CD123, which was detected in both cases, can be used as valuable tools in the diagnosis of this rare neoplasm.

show abstract

A Cutaneous Agranular CD2^–CD4⁺CD56⁺“Lymphoma”: Report of Two Cases and Review of the Literature

Cited by 51 publications

References 5 publications

Cutaneous Monomorphous CD4- and CD56-Positive Large-Cell Lymphoma

Cutaneous Monomorphous CD4- and CD56-Positive Large-Cell Lymphoma

Manifestations cutanées révélatrices d’une leucémie aiguë dendritique plasmocytoïde (LADP) : deux observations

CD4+/CD56+ Hematodermic Neoplasm

Contact Info

Product

Resources

About